FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Blouse Grant E. 2. Date of Event Requiring Statement (MM/DD/YYYY)
7/12/2021 

3. Issuer Name and Ticker or Trading Symbol CATALYST BIOSCIENCES, INC. [CBIO]
(Last)       (First)       (Middle)
C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Scientific Officer /
(Street)
SOUTH SAN FRANCISCO, CA 94080      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  1754 (1) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (2) 7/16/2028  Common Stock  30000  $12.21  D   
Stock Option (Right to Buy)   (3) 7/30/2028  Common Stock  10000  $9.68  D   
Stock Option (Right to Buy)   (4) 1/24/2029  Common Stock  18000  $7.97  D   
Stock Option (Right to Buy)   (5) 1/23/2029  Common Stock  35000  $6.85  D   
Stock Option (Right to Buy)   (6) 2/8/2031  Common Stock  38500  $5.89  D   
Stock Option (Right to Buy)   (7) 6/16/2031  Common Stock  25000  $4.33  D   

Explanation of Responses:
(1)  Includes shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on various dates between February 11, 2019 and February 9, 2021.
(2)  25% of the shares subject to the option vested on the one-year anniversary of the vesting commencement date of July 2, 2018, and 1/48 of the shares subject to the option vested or will vest on each monthly anniversary of the vesting commencement date thereafter.
(3)  25% of the shares subject to the option vested on the one-year anniversary of the vesting commencement date of July 1, 2018, and 1/48 of the shares subject to the option vested or will vest on each monthly anniversary of the vesting commencement date thereafter.
(4)  The option vested or will vest over a four (4) year period on each monthly anniversary of the vesting commencement date of January 24, 2019.
(5)  The option vested or will vest over a four (4) year period on each monthly anniversary of the vesting commencement date of January 23, 2020.
(6)  25% of the shares subject to the option will vest on the one-year anniversary of the vesting commencement date of February 8, 2021, and 1/48 of the shares subject to the option will vest on each monthly anniversary of the vesting commencement date thereafter.
(7)  25% of the shares subject to the option will vest on the one-year anniversary of the vesting commencement date of June 16, 2021, and 1/48 of the shares subject to the option will vest on each monthly anniversary of the vesting commencement date thereafter.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Blouse Grant E.
C/O CATALYST BIOSCIENCES, INC.
611 GATEWAY BOULEVARD, SUITE 710
SOUTH SAN FRANCISCO, CA 94080


Chief Scientific Officer

Signatures
/s/ Faisal Shawwa Attorney-in-Fact for Grant E. Blouse 7/15/2021
**Signature of Reporting Person Date
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Catalyst Biosciences Charts.
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Catalyst Biosciences Charts.